Evidence map›Paper›PMID 19203466›Full record

ArticleJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques2008

Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).

Mavanur R Suresh, Pravin K Bhatnagar, Dipankar Das

Open access · diamondAbstract read
In one paragraph

Article in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Broad-Spectrum Engineered Multivalent Nanobodies Against SARS-CoV-1/2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Face up to challenge of virology world.World journal of virology · 2012
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mavanur R SureshFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. msuresh@pharmacy.ualberta.ca
Pravin K Bhatnagar
Dipankar Das
University of Alberta · CA

Funding

Ultrasensitive Bispecific Antibody Assay for SARS VirusU01AI061233 · NIAID · UNIVERSITY OF ALBERTA · PI EL-KADI, AYMAN · 2005 to 2009
$964k
NIAID NIH HHS 5U01AI061233-02NIAID NIH HHS U01 AI061233
6 · The paper itself

Abstract

purposeThe large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.

methodsThis review describes the specific molecular targets for diagnostics and therapeutics of viral infection.

resultsThe three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.

conclusionNP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the avail ability of clinically relevant animal model.

Indexed as

Administration, IntranasalAnimalsAntibodies, ViralAntigens, ViralCanadaChlorocebus aethiopsEnzyme-Linked Immunosorbent AssayEpitopesNeutralization TestsNucleocapsid ProteinsReverse Transcriptase Polymerase Chain ReactionSevere Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusVero CellsViral Envelope ProteinsViral ProteinsAntibodies, ViralAntigens, ViralEpitopesNucleocapsid ProteinsViral Envelope ProteinsViral ProteinsViral Vaccines

Identifiers

PMID19203466
PMCPMC2678938
OpenAlexW2153703950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.